AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04747301 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dinoprostone 10mg (Propess)
Description: Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured.
Study NCT04798963 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Off-clamp partial nephrectomy
Description: Partial nephrectomy will performed without renal artery clamping
Study NCT04875975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive rozanolixizumab in a pre-specified sequence during the Treatment Period.
Study NCT04875975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive placebo in a pre-specified sequence during the Treatment Period.
Study NCT06440369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group
Description: The patient will perform an intermittent exercise which consists of nine 5-minute cycles with a succession of work (top: 1 minute; bottom: 4 minutes). The high-intensity work phase will be adjusted so as to achieve a target Heart Rate (HR) corresponding to resting HR + 80% reserve HR (reserve HR = (200 - age) - resting HR). The low-intensity work phase will be adjusted to achieve a target maximum HR corresponding to resting HR + 60% reserve HR. In total duration, the exercise presents a submaximal intensity, commonly used in exercise rehabilitation studies carried out with various pathologies. It is an intensity capable of promoting benefits on the cardiovascular aspect without representing a severe intensity for the patient.~In order to adapt the training and guarantee patient safety, the first exercise session will be carried out with an alternation between a high-intensity work phase of resting HR + 70% reserve HR and a work phase. at low intensity of resting HR + 50% reserve HR.
Study NCT06440369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity orientation group
Description: Every week, for around ten minutes, patients in the AP orientation group will be contacted by telephone. The main objective of this exchange is to provide targeted advice on physical activity, its role, its objectives as well as its different ways of carrying it out. The second objective is to provide each week a personalized objective for each patient which can evolve over the weeks to increase levels of physical activity as far as possible. During each call, the evaluator will practice reflective listening, ask open-ended questions to facilitate the exchange, value and summarize the patient.
Study NCT05094999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proprioceptive stimulations
Description: Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
Study NCT05094999 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulations
Description: Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
Study NCT05103748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional vestibular rehabilitation
Description: The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
Study NCT05103748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and vestibular dual task training
Description: The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
Study NCT05127551 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent Infinite
Description: Implantation of the iStent Infinite
Study NCT05127551 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor Device
Description: Implantation of competitor device
Study NCT05146817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral care
Description: Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
Study NCT05146817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral care
Description: Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
Study NCT06345417 — intervention group
Intervention type: OTHER
Intervention: Patient Blood Management (PBM)
Description: PBM is a strategy to manage the participant's own blood. Its focus is on anemia, bleeding and coagulation management.
Study NCT06345417 — intervention group
Intervention type: BIOLOGICAL
Intervention: Allogeneic transfusion
Description: Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
Study NCT06333132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss-induced Diabetes Remission
Description: Patients will undergo a dietary intervention plus drugs (if needed) with the purpose to obtain a 10% (or at least 10 kg) body weight reduction to achieve diabetes remission
Study NCT05589350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saturated fat intake
Description: Intake of saturated fat from yogurt and animal butter daily for 4-week period
Study NCT05589350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saturated fat intake
Description: Intake of saturated fat from yogurt and animal butter daily for 4-week period
Study NCT00860678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Study NCT00860678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no Intervention
Study NCT06468306 — intervention group
Intervention type: PROCEDURE
Intervention: non-invasive ventilation teraphy, NIV
Description: Routine management regimes of NIV
Study NCT05303883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Constrained Induced Movement Therapy
Description: Constraint of the child's less-impaired upper extremity for first 17 days of treatment. Children wear a removable, lightweight constraint for the first 17 of 20 therapy sessions.
Study NCT06192563 — intervention group
Intervention type: DRUG
Intervention: Dupilumab
Description: Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
Study NCT04671641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
Study NCT04671641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
Study NCT04911933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Therapy
Description: There will be systemic family psychotherapy sessions every two weeks. Families and individuals who require a more intensive service will be referred to a higher level of care.
Study NCT05577611 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Basic chemotherapy + UCB transplantation
Description: The basic chemotherapy regimen was the same as that of the control group~UCB micro transplantation scheme:~Aza 100mg, 75mg/m2/d, IVGTT, D-10 to D-4~Ara-C 1000mg/m2/q12h, IVGTT, D-3 to D-2~Single non consanguineous umbilical cord blood (NC > 1.5 \* 10 \^ 7 / kg), IVGTT, D0~Bone marrow aspiration smear, MRD and bone marrow chimerism were detected on D14, d30 and D60 after transplantation.
Study NCT06356116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: During hospitalization, physical therapist visits the patient once or twice on day one or two post-operative (treatments including bedside standing, ambulation, stepping, active-assisted range of motion exercises).~Educational material will be given at discharge from hospital.
Study NCT06356116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Description: Physical therapist visits 5 times during hospitalization, including~1. Pre-operatively: instruction regarding range of motion exercises, use of assistive device.~2. Post-operative day zero: bedside standing, ambulation, stepping, active-assisted range of motion exercises.~3. Post-operative day one: visit #1 continuing the day-zero exercises;~4. Post-operative day one: visit #2 mini-squat against wall; stair negotiation training (1/2 flight).~5. Post-operative day two: continuing the day-zero exercises; stair negotiation (1 flight); discharge from hospital in the afternoon.~After discharge from hospital: post-operative day three \~ week 4: telerehabilitation
Study NCT06000072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Exercise Program
Description: Core exercises
Study NCT06000072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Exercise Program
Description: Core exercises
Study NCT04812951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion
Description: one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
Study NCT04812951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cationorm eye drops
Description: one cationorm eye drop twice a day for 30 preoperative days
Study NCT04713371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Keytruda Injectable Product
Description: Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected.
Study NCT04713371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Yervoy Injectable Product
Description: Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected.
Study NCT04713371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytoxan
Description: Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.
Study NCT04713371 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryosurgical freezing (cryosurgery)
Description: Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.
Study NCT04713371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF Injectable
Description: Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
Study NCT05496816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAC in septic patients
Description: Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge.
Study NCT05373381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt
Description: Following a screening period, subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles. Patients will receive dietary advice from a Registered Dietitian (RD) to allow for the design of personalized meal plans maintaining carbohydrates up to 33% of total caloric intake, and be asked to maintain a daily dietary log. To assist patients in understanding, monitoring and controlling their dietary choices to maintain a low carbohydrate diet, they will be trained and receive assistance on the use of an online tool for tracking nutrition \[Healthtrac\].
Study NCT05653635 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous-integrated boost with IMRT
Description: Simultaneous-integrated boost guided by FDOPA-PET
Study NCT06044610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GENPOP Passive dehydration (75% reduction in fluid intake
Description: Over 24-hours
Study NCT06044610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GENPOP Ad lib fluid intake
Description: Over 24 hours
Study NCT06044610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE without fluid replacement
Description: 90-min standard cycling exercise trial in heat chamber
Study NCT06044610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EXERCISE with fluid replacement
Description: 90-min standard cycling exercise trial in heat chamber
Study NCT05676190 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CIK combined with chemotherapy group
Description: Combination of chemotherapy and autologous cytokine induced killer cells
Study NCT05676190 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CIK combined immunotherapy group
Description: Combination of immunotherapy and autologous cytokine induced killer cells
Study NCT05676190 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CIK combined targeted therapy group
Description: Combination of targeted therapy and autologous cytokine induced killer cells
Study NCT05676190 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CIK in combination with other therapies
Description: CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
Study NCT06170593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Injection
Description: 0.1mL of triamcinolone 1% solution per lesion
Study NCT04866069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine
Description: Adjuvanted inactivated vaccine
Study NCT04866069 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study NCT04757727 — intervention group
Intervention type: OTHER
Intervention: Decriptive study of EDB
Description: data on EDB will be register
Study NCT04848337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
Study NCT04848337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg orally daily.
Study NCT06467552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The entire process is carried out according to Severance Hospital surgical protocols.
Study NCT06467552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nucare Curact group
Description: The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery. In addition, the patients of control group will be instructed to take up to 4 doses of the nutritional supplement (Nucare Curact provided by DAESANG Wellife Inc.) per day for approximately 2 weeks before surgery and for about 4 weeks after surgery.
Study NCT05707455 — intervention group
Intervention type: OTHER
Intervention: evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
Description: evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
Study NCT05025280 — intervention group
Intervention type: OTHER
Intervention: Adolescent/Adult Sensory Profile Questionnaire
Description: The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking.
Study NCT06369142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Description: Intravascular lithotripsy (IVL) and ballons with a nominal rated burst pressure of ≤ 18 atm
Study NCT06369142 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard non-IVL methods
Description: Standard non-IVL methods treating severely calcified lesions such as special high, super high and cutting balloons and ablative procedures
Study NCT06249464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation
Description: All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.
Study NCT06249464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation
Description: All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.
Study NCT06249464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
Study NCT05712018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch coload - 0 ml/kg
Description: No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.